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Background: Methionine adenosyltransferase 2A (MAT2A) is an enzyme that catalyzes the formation of
S-adenosylmethionine (SAMe) by joining methionine and ATP. SAMe is a methyl donor for transmethylation
and has an important role for DNA and/or protein methylation. MAT2A is expressed widely in many tissues
especially in kidney. Several studies have demonstrated that there are abnormal expressions of MAT2A in
several kinds of cancers such as liver and colon cancers. But the relationship of MAT2A between renal cell
carcinomas (RCC) is less understood.
Methods: The mRNA expression level of the MAT2A gene was determined in 24 RCC patients and 4 RCC cell lines,
using real-time quantitative-polymerase chain reaction (RT-PCR). The MAT2A protein content was measured by western
blotting and immunohistochemical analysis in 55 RCC patients. The mRNA levels of heme oxygenase-1 (HO-1) and
cyclooxygenase-2 (COX-2) were also analysized in patients using RT-PCR. The correlations between the MAT2A and
HO-1 as well as COX-2 were analyzed with nonparametric Spearman method.
Results: MAT2A transcript was significantly downregulated in cancer tissues compared to normal tissues (P < 0.05).
Immunohistochemical analysis and western blotting indicated that level of MAT2A protein was decreased in cancer
tissues. The statistical analysis reveals a negative correlation between MAT2A and HO-1 expression in RCC patients and
cell lines (P < 0.01).
Conclusions: This study demonstrated that MAT2A was lower expression in cancer tissues, suggesting that it may be
involved in the development of RCC. MAT2A is a transcriptional corepressor for HO-1 expression by supplying SAM for
methyltransferases, which may be one of potential mechanism of MAT2A as tumor suppressor in kidney carcinogenesis.
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Kidney cancer is among the 10 most common cancers,
which accounts for 2% to 3% of all adult malignancies
and causes 100,000 deaths per year worldwide [1]. The
most common hisitologic subtype of kidney cancer is
renal cell carcinomas (RCC), of which 70–80% of cases
are defined as clear cell renal cell carcinoma (ccRCC)* Correspondence: caizhiming2000@163.com
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unless otherwise stated.[2]. RCC is generally resistant to chemotherapy and radi-
ation therapy [3]. Radical or partial nephrectomy of the
tumor at an early stage remains the mainstay of curative
therapy nevertheless up to 40% of the patients relapse
after surgery [4]. Unlike other solid malignancies, methods
for RCC early diagnosis are lacking but they are critically
important because therapeutic efficacy and, hence, sur-
vival are tightly linked to the time of diagnosis. Distant
metastases are present at the time of initial diagnosis in
approximately one third of patients, and the tumor will
recur in another third, even after nephrectomy with cura-
tive intent [5]. Better understanding of the molecular
mechanisms of RCC may hasten identification of newtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of the clinical characteristics of 55 RCC
patients
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and therapeutic strategies.
Cancer cell metabolism is significantly altered com-
pared with metabolism of normal cells. Significant pro-
gresses on genetics of renal cancer have proved that it is
a metabolic disease [6]. Several known genes related kid-
ney cancer, such as von Hippel-Lindau (VHL), fumarate
hydratase (FH) and succinate dehydrogenase (SDH) are
involved in pathways that respond to metabolic stress
[7]. VHL loss can increase the expression of hypoxia-
inducible factors, which affect several metabolic path-
ways, including glycolysis and oxidative phosphorylation
[8]. The mutations of FH and SDH are associated with
dysfunction of tricarboxylic acid cycle [9,10]. So, it will
provide the foundation for the development of effective
therapy for kidney cancer to understand the metabolic
basis of this disease [11].
One-carbon metabolism can integrate nutritional sta-
tus from amino acids, glucose and vitamins, which is im-
portant for the biosynthesis of lipids, nucleotides and
proteins, the maintenance of redox status and the sub-
strates for methylation reactions [12]. One-carbon me-
tabolism involves in the folate and methionine cycles.
The related enzymes involved folate metabolism have been
discovered to be associated to RCC risk [13,14]. The abnor-
mality of methionine cycle was identified in many kinds of
cancers [15,16]. But, the relationship between methionine
metabolism and RCC is poorly understood. Methionine
adenosyltransferase (MAT) is an essential cellular en-
zyme that catalyzes the formation of S-adenosylmethionine
(SAMe), the principal biological methyl donor [17]. In
mammals, this essential enzyme is the product of two
different genes, MAT1A and MAT2A, which display a
distinct pattern of expression among different tissues.
MAT1A is the predominant enzyme in liver parenchymal
cells, while MAT2A is expressed in all other tissues [18].
However, the relationship between the expression of
MAT2A and RCC development is still unknown. In this
study, we investigated expression levels of MAT2A gene
and protein in RCC specimen and cell lines. Then, we also
determined the association between MAT2A expression
and other RCC related genes’ expressions to understand
the potential mechanism underlying MAT2A involved in
RCC carcinogenesis. Our results suggest that MAT2A is
downregulated in cancer tissues of RCC patients and has
function of tumor suppressor though repressing the ex-
pression of heme oxygenase-1 (HO-1).
Methods
Patients and tissue specimens
A total of 55 paired ccRCC cancer tissues and adjacent
normal tissues samples were obtained from the Biobank
of Complex Diseases in Shenzhen between 2010 and
2012 in China. The adjacent normal tissues were definedas kidney tissues located 2.0 cm outside of visible ccRCC
lesions. All the 55 patients’ survival information was re-
ceived by telephone. The median follow-up period was
69 months (range: 4 ~ 116 months). Patients’ clinical
characteristics (gender, age, size, nodal status, metastasis
and Fuhrman Nuclear Grade) were obtained from the
medical records (Table 1). No any treatment (chemo-
therapy or radiation) was used before the operation.
All resection samples were confirmed to be ccRCC
by clinical pathology and carbonic anhydrase 9 (CA-9)
measurements (Additional file 1: Figure S1). The collec-
tion and use of the patient samples were reviewed and
approved by Institutional Ethics Committees of Peking
University Shenzhen Hospital, and written informed con-
sent from all patients was appropriately obtained. Frozen
tissues from 24 ccRCC cancer and adjacent normal sam-
ples were randomly selected from all 55 paired samples
for extraction of total RNA.
Cell culture
The human renal cancer cell lines (ACHN, Caki-1,769-P
and 786-O) and embryonic kidney cell (HEK293) were
obtained from cell resource center of Shanghai Institutes
for Biological Sciences, Chinese Academy of Science.
All cells were maintained in Dulbecco’s modified Eagle’s
medium (GIBCO, Grand Island, USA) supplemented with
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50 U/mL penicillin and 50 μg/mL streptomycin. Cells
were grown in a humidified atmosphere with 5% CO2 at
37°C. Cells were collected for following study.
RNA extraction and cDNA synthesis
Total RNA was extracted from cancer tissues, normal
adjacent tissues and 5 cells with Trizol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
protocol. The concentration of total RNA was deter-
mined using a NanoDrop ND-1000 spectrophotometer
(Thermo Scientific, Wilmington, DE, USA). Then, cDNA
was synthesized from 1 μg of total RNA using a Fermentas
RT system (Thermo Scientific, Wilmington, DE, USA), ac-
cording to the manufacturer’s instructions. Reverse tran-
scription reactions were carried out at 25°C for 5 mins
and followed by 42°C for 60 mins.
Quantitative real-time polymerase chain reaction
(qRT-PCR)
The mRNA expression levels were analyzed using SYBR
Premix Ex TaqTM II (Takara, Dalian, China), with β-
Actin as an internal reference. qRT-PCR was performed
in 20 μl reaction mixture containing 10 μl of SYBR
Premix, 0.5 μM of forward and reverse primers, and
1 μl template cDNA on LightCycler480 System (Roche,
Foster City, CA, USA). The primers were designed ac-
cording to the human MAT2A, CA-9, heme oxygenase-1
(HO-1), cyclooxygenase-2 (COX-2) and β-Actin genes se-
quences reported in GenBank. The primer sequences were
synthesized by Invitrogen (Guangzhou, China) as follows:




CA-9, Forward primer: 5′- GGATCTACCTACTGTT
GAGGCT-3′,
Reverse primer: 5′- CATAGCGCCAATGACTCTGGT-3′;
HO-1, Forward primer: 5′-ATGACACCAAGGACCA
GAGC -3′,
Reverse primer: 5′-GTGTAAGGACCCATCGGAGA -3′;








All reactions were incubated at 95°C for 5 min, followed
by 40 cycles of 95°C for 10 s, 60°C for 20 s and 72°C
for 30 s. PCR reactions of each sample were conducted in
duplicate. Data were analyzed through the comparative
threshold cycle (CT) method.Western blotting
Five cells, cancer tissues and adjacent normal tissues from
all patients were homogenized in radioimmunoprecipita-
tion assay buffer (RIPA) containing the protease inhibi-
tors phenylmethylsulfonyl fluoride (100 μg/mL), cocktail
(1 mmol/L) and dithiothreitol (0.5 mmol/L). Homoge-
nates were centrifuged and supernatants were collected.
Protein concentrations were determined by bicinchoninic
acid (BCA) protein assay kit (Thermo Pierce ). A total of
50 μg of protein from each sample was resolved by redu-
cing loading buffer and separated by 10% sodiumdodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
followed by electrophoretic transfer to a polyvinylidene
difluoride (PVDF) membrane. The PVDF membrane was
saturated with 5% skim milk in TBST (50 mM Tris–HCl,
150 mM NaCl, 0.1% Tween-20) for 2 h and then incubated
with primary antibodies at 4°C overnight. The primary
antibodies used included rabbit polyclonal antibodies to
MAT2A (1:1000, Abcam, Hong Kong, China), HO-1
(1:200, Santa Cruz, Shanghai, China) and β-actin (1:5,000,
Abcam, Hong Kong, China). The specificity of the MAT2A
antibody has been determined (Additional file 2: Figure S2).
PVDF membrane was incubated with 1:10,000-diluted
peroxidase-coupled goat anti-rabbit immunoglobulin G
(IgG) (secondary antibody, EarthOx, San Francisco, USA)
for 1 h, after washing three times with TBST (5 min/time)
at room temperature. After further washing with TBST
four times, the PVDF membrane was exposed to enhanced
chemiluminescence substrate (Millipore, Rockford, USA)
for 30 min and detection was performed using a film.
Immunohistochemical analysis
Paraffin sections (3 μm) from samples of 55 ccRCC sam-
ples and adjacent normal samples were deparaffinized in
100% xylene and re-hydrated in descending ethanol
series (100%, 90%, 80%, 70% ethanol) and water accord-
ing to standard protocol. Heat-induced antigen retrieval
was performed in 10 mM citrate buffer for 2 min at
100°C. Endogenous peroxidase activity and non-specific
antigen were blocked with peroxidase blocking reagent
containing 3% hydrogen peroxide and serum, followed by
incubation with rabbit anti-human MAT2A antibody for
1 h at 37°C. After washing, the sections were incubated
with biotin-labelled goat anti-rabbit antibody for 10 min
at room temperature, and subsequently were incubated
with streptavidin-conjugated horseradish peroxidase (HRP)
(Maixin Inc, China). The peroxidase reaction was devel-
oped using 3, 3-diaminobenzidine chromogen solution in
DAB buffer substrate. Sections were visualized with DAB
and counterstained with hematoxylin, mounted in neutral
gum, and analyzed using a bright field microscope.
All of the IHC staining results were reviewed independ-
ently by two pathologists. Positive expression of MAT2A
was defined as the brown staining in the cytoplasm and
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titatively scored. Intensity was estimated in comparison to
the control and scored as follows: 0, negative staining; 1,
weak staining; 2, moderate staining; and 3, strong staining.
Scores representing the percentage of tumor cells stained
positive were as follows: 0, no positive cell; 1, <5%; 2, 6–
25%; 3, 26–50%; 4, 51–75%; and 5, > 75%. A final score
was calculated by multiplying the scores for intensity and
percentage.
Statistical analysis
Statistical analysis was carried out using the SPSS 13.0
statistical software package. qRT-PCR and immunohisto-
chemical data were analyzed by two-tailed paired t-test
and Mann–Whitney U test (α = 0.05). The nonparametric
Spearman rank correlation coefficient was used to calcu-
late the correlation between the MAT2A and HO-1 as
well as COX-2 expressions. For all analyses, p < 0.05 was
considered significant.Figure 1 The mRNA level analysis of the MAT2A in RCC patients and
extracted and reverse transcripted to cDNA. Then, real-time qRT-PCR was c
A. Relative mRNA expression level of MAT2A in RCC cancer tissues and pai
level of MAT2A was lower in RCC cancer tissues (C) than in paired normal
MAT2A was lower in 4 RCC cell lines than in HEK293.Result
Downregulated mRNA expression of MAT2A in ccRCC
patients and kidney cancer cell lines
MAT2A expression in ccRCC has yet to be explored.
Therefore, we first examined the transcription level of
the MAT2A in cancer tissues and adjacent normal tis-
sues from 24 RCC patients using qRT-PCR. Analysis of
mRNA levels reveals 19/24 (79.2%) of RCC patients have
reduced MAT2A mRNA level in cancer tissues. More-
over, 16/24 patient samples (66.7%) demonstrated a
greater than twofold reduction (Figure 1A). Overall, the
average reduction in MAT2A mRNA levels was 3.4 fold
(P < 0.05, Figure 1B). Otherwise, the mRNA expressions
in all four RCC cell lines were also downregulated rela-
tive to HEK293.
Reduced protein content of MAT2A in ccRCC
To support the change in mRNA level, the protein content
of MAT2A was further measured by immunohistochemicalcell lines. Total RNA of 24 RCC patients and 4 RCC cell lines was
arried out to determine the mRNA expression levels of MAT2A.
red normal tissues of 24 RCC patients. B. Relative mRNA expression
tissues (N) (n = 24; P < 0.05). C. Relative mRNA expression level of
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examinations indicated that MAT2A protein is mainly
present in nuclei and level of it was obviously down-
regulated in cancer tissues compared to adjacent normalFigure 2 The protein expression level of MTA2A in RCC patients. A-D
content was obviously lower in cancer tissues (C and D) than in normal tis
E Level of MAT2A protein was lower in RCC cancer samples (C) than in pai
were semiquantitatively scored according to staining intensity and percent
F Western blotting analysis of MAT2A. The protein expression level of MAT2Atissues (Figure 2A-D). The lower level is approxi-
mately 3.4 times (P < 0.001, Figure 2E). The western
blotting analysis showed similar trend with immuno-
histochemical result in that protein content of MAT2AImmunohistochemical analysis of MAT2A expression. MAT2A protein
sues (A and B). Magnifications × 200 (A and C) and × 400 (B and D).
red normal tissuesamples (N) (n = 55, P < 0.001). The MAT2A protein
age in immunohistochemical analysis of cancer or adjacent tissues.
was lower in RCC cancer tissues (C) than in paired normal tissues (N).
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sues (Figure 2F).
Negative correlation of gene expression between MAT2A
and HO-1
In order to understand the potential mechanism of
MAT2A, we further measure the expressions of two kid-
ney cancer related genes COX-2 and HO-1 in RCC pa-
tients and cell lines. The results indicate that both genes
are highly expressed in cancer tissues than in adjacent
normal tissues (P < 0.01, Figures 3A and 3B).The mRNA
levels are also upregulated in four RCC cell lines than in
HEK293 (Figures 3C). The protein content of HO-1 is
obviously higher in four RCC cell lines than in HEK293
while MAT2A shows the opposite style (Figures 3D).
The statistical analysis reveals a negative correlation
between MAT2A and HO-1 expression in RCC patients
(P < 0.01, Figures 3E). The correlation between MAT2A
and HO-1 is also negative in cell lines (Additional file 3:
Figure S3). But, there is no significant correlation
between MAT2A and COX-1 (Figures 3F).Figure 3 The negative correlation between MAT2A and HO-1 express
qRT-PCR. The correlation analysis was performed between MAT2A and HO-
levels of HO-1 (A) and COX-2 (B) were higher in RCC cancer tissues (C) tha
expression level of HO-1 and COX-2 were higher in 4 RCC cell lines than in
lines.The correlation of protein content between MAT2A and HO-1 is nega
MAT2A and HO-1 expression in RCC patients (P < 0.01). F The statistical ana
expression in RCC patients.Discussion
Both DNA and histone methylation are important regula-
tors for gene expression and chromatin structure, which
have multiple effects on carcinogenesis [19,20], but the de-
tailed mechanism is required to be determined. As a me-
thyl donor, SAMe also plays vital role in gene expression
via its effect on methylation [21]. So, MAT2A has a poten-
tial effect on tumor development and progression [22].
Recent studies have illustrated there are abnormal expres-
sions of MAT2A in some tumors, including liver, gastric
and colon cancers [23-25]. In our study, the content of
MAT2A is obviously decreased in cancer tissue of RCC
patients under mRNA and protein levels. So, MAT2A
functions as a tumor suppressor in RCC. An increasing
number of studies have suggested that MAT2A plays
an important pathogenetic role in facilitating liver and
colon cancer growth [26,27]. Our results further provide
evidence that abnormal MAT2A is also a factor of RCC
development.
Previous studies have indicated HO-1 and COX-2 are
regulated by MAT2A [28]. HO-1 is an enzyme that catalyzes
the degradation of heme and affords protection againstion. mRNA levels of HO-1 and COX-2 were analyzed with real-time
1 as well as COX-2 in RCC patients. A and B Relative mRNA expression
n in paired normal tissues (N) (n = 24; P < 0.05). C Relative mRNA
HEK293. D The western blotting analysis of MAT2A and HO-1 in cell
tive. E The statistical analysis reveals a negative correlation between
lysis reveals no significant correlation between MAT2A and COX-2
Figure 4 The proposed model of MAT2A role on RCC development. The lower content of MAT2A level reduces the product of S-
adenosylmethionine (SAMe) and then decreases the level of methylation, which leads to the reactivation of HO-1 expression to increase the cell
proliferation and inhibit cell apoptosis.
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hydratase deficient kidney cells survival and inhibition
of it can lead to cell death [29]. It has been demon-
strated HO-1 is often overexpressed in RCC patients
and cell lines, and promotes survival of renal cancer
cells [30,31]. COX-2 is an enzyme which catalyzes the
synthesis of prostaglandins from arachidonic acid. It
has been also demonstrated that COX-2 is increased
in RCC and plays an important role in the prolifera-
tion of malignant renal cells [32,33]. Our results also
confirmed both HO-1 and COX-2 are upregulated in
RCC patients and cell lines, but further evidence indi-
cates MAT2A is negative correlation with HO-1, no
COX-2. It means that MAT2A biological role in RCC
seems to be mainly associated with HO-1.
It has been indicated MAT2A can inhibit the expres-
sion of HO-1 as a transcriptional corepressor [28], which
supplies SAMe for DNA and histone methyltransfer-
ases. MAT2A can interact with many chromatin-related
proteins of diverse functions such as histone modifi-
cation, chromatin remodeling, transcription regulation,
and nucleo-cytoplasmic transport [34]. DNA methylation
and histone modification are known to be closely related
to carcinogenesis and cancer progression [35]. So, lower
level of MAT2A can re-activate HO-1 to promote cell
proliferation because of reducing methylation on HO-1
promoter. Accordingly, we propose the possible mechan-
ism underlying MAT2A involved in RCC development
(Figure 4).
Conclusion
In summary, our results reveal that downregulated ex-
pression level of MAT2A is common in cancer tissues ofRCC patients. The reduced MAT2A may derepress the
expression of HO-1 through lowering DNA and/or his-
tone methylation, which can be considered as potential
cause of MAT2A involved RCC suppression. The results
also imply that identification of other genes regulated by
MAT2A during RCC development will expand our un-
derstanding of the carcinogenesis and screening strat-
egies in RCC. Because samples in our study are limited,
whether MAT2A can be as biomarker for the early diag-
nosis of RCC and prognostic evaluation is to be further
determined. Our study only provides a possible mechan-
ism of MAT2A biological role, so additional research
is also required to determine the link between lower
MAT2A levels and RCC development.Additional files
Additional file 1: Figure S1. The mRNA level analysis of the CA-9 in
RCC patients. Relative mRNA expression level of carbonic anhydrase 9 in
RCC cancer tissues and paired normal tissues of RCC patients.
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